Atherogenesis, atherosclerosis and related diseases: unresolved issues

References

[1] Schwartz CJ,Sprague EA.A modern view of atherogenesis..Am J Cardiol1993;71:9B-14

[2] Summerhill V.Pericytes in atherosclerosis..Adv Exp Med Biol2019;1147:279-97

[3] Orekhov AN,Novikov ID,Andreeva ER.Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells..Exp Mol Pathol1985;42:117-37

[4] Orekhov AN.LDL and foam cell formation as the basis of atherogenesis..Curr Opin Lipidol2018;29:279-84

[5] Ellulu MS,Khaza’ai H,Abed Y.Atherosclerotic cardiovascular disease: a review of initiators and protective factors..Inflammopharmacology2016;24:1-10

[6] Morita SY.Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis..Biol Pharm Bull2016;39:1-24

[7] Arnao V,Daidone M.Lipoproteins in atherosclerosis process..Curr Med Chem2019;26:1525-43

[8] Nakajima K.Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis..Clin Chim Acta2018;478:200-15

[9] Basatemur GL,Clarke MCH,Mallat Z.Vascular smooth muscle cells in atherosclerosis..Nat Rev Cardiol2019;16:727-44

[10] Maguire EM,Xiao Q.Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease..Vascul Pharmacol2019;112:54-71

[11] Alipov VI,Karagodin VP,Orekhov AN.Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference?.Vessel Plus2017;1:107-15

[12] Summerhill VI,Yet SF,Orekhov AN.The atherogenic role of circulating modified lipids in atherosclerosis..Int J Mol Sci2019;20:E3561 PMCID:PMC6678182

[13] Orekhov AN.Modified and dysfunctional lipoproteins in atherosclerosis: effectors or biomarkers?.Curr Med Chem2019;26:1512-24

[14] Orekhov AN.Modified lipoproteins as biomarkers of atherosclerosis..Front Biosci (Landmark Ed)2018;23:1422-44

[15] Borén J.The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity..Curr Opin Lipidol2016;27:473-83

[16] Hurt-Camejo E.ApoB-100 lipoprotein complex formation with intima proteoglycans as a cause of atherosclerosis and its possible ex vivo evaluation as a disease biomarker..J Cardiovasc Dev Dis2018;5:E36 PMCID:PMC6162553

[17] Chistiakov DA,Myasoedova VA,Orekhov AN.Mechanisms of foam cell formation in atherosclerosis..J Mol Med (Berl)2017;95:1153-65

[18] Bäck M,Tabas I,Kovanen PT.Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities..Nat Rev Cardiol2019;16:389-406 PMCID:PMC6727648

[19] Poznyak AV,Melnichenko AA,Sukhorukov V.Signaling pathways and key genes involved in regulation of foam cell formation in atherosclerosis..Cells2020;9:E584 PMCID:PMC7140394

[20] Albany CJ,Giganti G,Scottà C.Getting to the heart of the matter: the role of regulatory T-cells (Tregs) in cardiovascular disease (CVD) and atherosclerosis..Front Immunol2019;10:2795 PMCID:PMC6894511

[21] Nasser MI,Huang H,Wang B.Macrophages: first guards in the prevention of cardiovascular diseases..Life Sci2020;250:117559

[22] Shi X,Lv Q,Wang F.Calcification in atherosclerotic plaque vulnerability: friend or foe?.Front Physiol2020;11:56 PMCID:PMC7013039

[23] Wang C.Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence..Circ Res2012;111:245-59

[24] Yao YG,Feng X,McCoy JP Jr.Accumulation of mtDNA variations in human single CD34+ cells from maternally related individuals: effects of aging and family genetic background..Stem Cell Res2013;10:361-70 PMCID:PMC4154056

[25] Sobenin IA,Bobryshev YV,Orekhov AN.Mitochondrial mutations in atherosclerosis: new solutions in research and possible clinical applications..Curr Pharm Des2013;19:5942-53

[26] Sobenin IA.Parine NR.Mitochondrial DNA damage in atherosclerosis..Genetic Polymorphisms.2017;CroatiaInTech139-58

[27] Volobueva A,Yet SF,Orekhov A.Changes in mitochondrial genome associated with predisposition to atherosclerosis and related disease..Biomolecules2019;9:377 PMCID:PMC6723661

[28] Sazonova MA,Sinyov VV,Khasanova ZB.Creation of cultures containing mutations linked with cardiovascular diseases using transfection and genome editing..Curr Pharm Des2019;25:693-9

[29] Sazonova MA,Ryzhkova AI,Khasanova ZB.Creation of cybrid cultures containing mtDNA mutations m.12315G>A and m.1555G>A, associated with atherosclerosis..Biomolecules2019;9:499 PMCID:PMC6770504

[30] Sobenin IA,Sinyov VV,Kalmykov VA.Editing of mitochondrial genome: cationic liposomes as the perspective mean of targeted delivery of nucleic acids into mitochondria..Arch World Mitochondria Soc2019;5:79

[31] Nemtsova V,Ilchenko I.Age-associated features of oxidative stress as marker of vascular aging in comorbid course of hypertension and type 2 diabetes mellitus..Vessel Plus2018;2:27

[32] Archakova T.Risk factors for atherosclerosis and vascular calcification in patients with type 2 diabetes on long-term hemodialysis..Vessel Plus2018;2:34

[33] Sazonova MA,Ryzhkova AI,Khasanova ZB.MtDNA mutations linked with left ventricular hypertrophy..Vessel Plus2019;3:5

[34] Sobenin IA,Khasanova ZB,Kirichenko TV.Carotid atherosclerosis-related mutations of mitochondrial DNA do not explain the phenotype of metabolic syndrome..Vessel Plus2019;3:14